Degarelix
- Generic Name
- Degarelix
- Brand Names
- Firmagon, Degarelix Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C82H103ClN18O16
- CAS Number
- 214766-78-6
- Unique Ingredient Identifier
- SX0XJI3A11
- Background
Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.
- Indication
Degaralix is used for the management of advanced prostate cancer.
- Associated Conditions
- Advanced Prostate Cancer
Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer
- First Posted Date
- 2019-05-13
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 8
- Registration Number
- NCT03947151
- Locations
- 🇫🇷
Hôpital Antoine Béclère, Clamart, France
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
- Conditions
- Cancer of Prostate
- Interventions
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Cancer Research Antwerp
- Target Recruit Count
- 202
- Registration Number
- NCT03899077
- Locations
- 🇧🇪
AZ Sint-Jan, Brugge, Belgium
🇧🇪OLVZ Aalst, Aalst, Belgium
🇧🇪CH Jolimont, Haine-Saint-Paul, Belgium
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
- Conditions
- Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 59
- Registration Number
- NCT03689699
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
- Conditions
- Castration Levels of TestosteroneMetastatic Prostatic AdenocarcinomaStage IV Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
- Interventions
- Procedure: OrchiectomyOther: Quality-of-Life AssessmentRadiation: Radiation TherapyProcedure: Radical Prostatectomy
- First Posted Date
- 2018-09-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1273
- Registration Number
- NCT03678025
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Parkland Memorial Hospital, Dallas, Texas, United States
🇺🇸UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Radiation: Stereotactic Body Radiation TherapyRadiation: Radium Ra 223 DichlorideOther: Laboratory Biomarker Analysis
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 25
- Registration Number
- NCT03361735
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-11-30
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 30
- Registration Number
- NCT03358563
- Locations
- 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Long Antagonist Protocol for IVF With Single Luteal Dose of Degarelix
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Assisting Nature
- Target Recruit Count
- 120
- Registration Number
- NCT03240159
- Locations
- 🇬🇷
Assisting Nature, Thessaloníki, Greece
Phase IV Study to Evaluate Bone Mineral Density in No-bone Metastatic Prostate Cancer Treated With Degarelix
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2017-06-28
- Target Recruit Count
- 35
- Registration Number
- NCT03202381
- Locations
- 🇮🇹
Clinical Department of Urology, university Hospital Spedali Civili di Brescia, Brescia, Italy
Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Ferring Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT03193645
- Locations
- 🇫🇷
Hopital de la Source (there may be multiple sites in this country), Orléans, France
Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy
- Conditions
- ProstatectomyNeoadjuvant TherapyProstate CancerAndrogen Antagonists
- Interventions
- First Posted Date
- 2017-03-15
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 90
- Registration Number
- NCT03080116
- Locations
- 🇧🇪
University Hospitals Leuven, Leuven, Vlaams-brabant, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.